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Abstract
Background: The objective of this study was to determine the rate of blood pressure control
according to 4 sets of Canadian guidelines published over a decade in patients with diabetes mellitus
attending Diabetes Centres in the province of Nova Scotia.
Methods: One hundred randomly selected charts from each of 13 Diabetes Centres audited
between 1997 and 2001 were extracted from the Diabetes Care Program of Nova Scotia Registry.
Multivariate logistic regression analyses examined the relationship between individual
characteristics and self-reported antihypertensive use. Included were 1132 adults, mean age 63
years (48% male), with 9 years mean time since diagnosis of diabetes.
Results:  According to the 1992 guidelines, 63% of the patients and according to the 2003
guidelines, 84% of patients were above target blood pressure or receiving antihypertensive
medications. Forty-seven percent of patients are considered to be hypertensive and not on
treatment according to 2003 guidelines. The results of the multivariate analyses showed that the
only factors independently associated with anti-hypertensive use was oral anti-hyperglycemic use.
Conclusion:  Hypertension is an additional risk factor in those with diabetes mellitus for
macrovascular and microvascular complications. The health and budgetary impacts of addressing
the treatment gap need to be further explored.
Background
Achievement of target blood pressures in hypertensive
patients is often difficult. In Halifax County, Nova Scotia,
57% of men and 42% of women with hypertension were
not well controlled[1]. Adequate blood pressure control is
of particular concern in patients with diabetes as hyper-
tension increases morbidity and mortality associated with
stroke and cardiovascular disease[2,3], as well as microv-
ascular complications such as retinopathy and nephropa-
thy[4]. Cardiovascular disease rates have been shown to
be 2–4 times higher in diabetes than in matched non-dia-
betic populations[5,6].
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A Canadian study reported 43% of people (age 18–74
years) had an optimal blood pressure (<120/80 mmHg),
and of those with a diagnosis of hypertension, only 13%
were below target (defined as 140/90 mm Hg). In this
study, about 50% of patients with diabetes were hyperten-
sive, and of these only 9% were under control[7]. An
internal review at the Diabetes Care Program of Nova Sco-
tia (DCPNS) from 1997–2001 showed that only 27.5% of
a random selection of patients attending Diabetes Centres
fell within the recommended target blood pressure for
people with a diagnosis of diabetes (< 130/85 mm Hg)
[8].
The United Kingdom Prospective Diabetes Study
(UKPDS) emphasized the need for adequate blood pres-
sure control in type 2 diabetes. The evidence suggested
that good blood pressure control may be as important if
not more important than blood glucose control in reduc-
tion of the cardiovascular complications[3,9,10]. Further,
adequate blood pressure control in the UKPDS decreased
risk for multiple diabetes end-points: 32% in deaths
related to diabetes; 44% decreased risk of stroke; and a
34% reduction in risk for all macrovascular diseases, as
well as a significantly decreased risk for other complica-
tions. [4] Clinical trials and epidemiologic studies have
suggested the target blood pressure goal of <130/80
mmHg[11-14].
The treatment of hypertension in patients with diabetes
has changed over the last decade. Studies and Clinical
Practice Guidelines for the management of hypertension
in patients with diabetes suggest lower blood pressure tar-
gets for diagnosis and control than for the general
population[11,15-17].
This study determined the degree of blood pressure con-
trol in patients with diabetes according to four sets of
Canadian Clinical Practice Guidelines published between
1992 and 2003[2,18-20] and described demographic and
treatment variables associated with antihypertensive
treatment.
Methods
The cohort was selected as part of a DCPNS (Diabetes
Care Program of Nova Scotia) internal audit of approxi-
mately 100 records from each of 13 Diabetes Centres
between 1997 and 2001. All patients were referred to the
Diabetes Centre following a diagnosis of diabetes by a
physician. Information gathered included: age, gender,
weight, blood pressure, duration of diabetes, serum creat-
inine, urinary protein and specific antihypertensive treat-
ment regimens. The mercury sphygmomanometer was
used for blood pressure measurement and recorded by
nurses and averaged over all visits for all individuals. The
nurses were aware of the correct procedure for obtaining a
blood pressure measurement, and performed the proce-
dure regularly. Eligibility criteria for the cohort included
being a non-pregnant adult over the age of 19; a diagnosis
of type 1 or 2 diabetes; a visit to the centre within 12
months of the audit date; and at least 15 months of
followup.
The final cohort included 1132 subjects. The population
consists of both genders (48% male), with an average age
of 63 (SD 12). Over 95% of patients had type 2 diabetes,
and the average length of time since diagnosis was 9.3 (SD
8) years previous. Average scores were obtained for most
tests and attributes. Kidney function was estimated using
both Couchoud cutpoints and the Cockroft-Gault for-
mula [21,22] Drug information was reclassified using the
WHO Anatomical Therapeutic Chemical (ATC) catego-
ries[23]. Prevalence of hypertension and trends in Clinical
Practice Guidelines over time were determined.
Guidelines used for analysis included the following: 1992
Clinical Practice Guidelines for Treatment of Diabetes
Mellitus – hypertension subcategory [18]; 1998 Clinical
Practice Guidelines for the Management of Diabetes in
Canada – hypertension subcategory [2]; 1999 Canadian
Hypertension Society Recommendations for the Manage-
ment of Hypertension – diabetes subcategory [19]; 2003
Canadian Hypertension Society Recommendations for
the Management of Hypertension – diabetes
subcategory[20].
Hypertension was defined using anti-hypertensive drug
use and blood pressure records. Patients with any antihy-
pertensive drug use and/or average blood pressure above
the guideline cutpoints (systolic, diastolic, or both) were
designated to be hypertensive. Rates and risk factors for
hypertension were calculated for each specific guideline.
Logistic regression was performed to determine predictors
of antihypertensive treatment.
SAS version 8.2 (SAS Institute, Cary, NC, USA, 2001) was
used for analysis.
Results
The use of the 2003 guidelines (target blood pressure:
systolic < 130 mmHg; diastolic < 80 mmHg) increased the
percentage of patients not meeting target to 84% from
63% using 1992 guidelines (target blood pressure: systolic
< 140 mmHg; diastolic <90 mmHg). Those considered to
be hypertensive and not on treatment increased to 47%
using the 2003 guidelines from 26% with the 1992 guide-
lines. (Figure 1); Clinical Practice Guidelines Effects on
Nova Scotia Patients with Diabetes Classified as Hyper-
tensive; Blank cells indicate that the category was not
applicable for that guideline. The "Isolated Systolic" cate-
gory in the 1999 and 2003 guidelines is usedCardiovascular Diabetology 2005, 4:11 http://www.cardiab.com/content/4/1/11
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synonymously with the "Elderly" category used in the
1998 guidelines for data display purposes) Among all
potential predictors of antihypertensive drug treatment
related to the 2003 guidelines included in our database,
only the patients receiving oral antihyperglycemics with
or without insulin were more likely to be treated. (Table
1: Predictors of Treatment among Patients with Hyperten-
sion, 2003 Guidelines)
Discussion
Many Nova Scotia patients with diabetes mellitus had
uncontrolled blood pressure and were not receiving anti-
hypertensive medication. Achieving control of high blood
pressure may be more important for long-term outcomes
than glycemic control[3,10]. The rates were similar to
other studies where 54–58% were above target blood
pressure and 22–28% were not receiving antihypertensive
treatment [24,25]. These populations have a decreased
prevalence of hypertension, yet a higher rate of treatment
in those affected.
Changing Clinical Practice Guidelines affect the criteria
for diagnosis, the treatment targets, the population to be
treated and the type of treatment. Many patients with dia-
betes mellitus previously considered to be normotensive
are now above the defined cutpoints. Adherence to the
newer guidelines would result in more patients being
treated and increased drug expenditures, but may lead to
decreased overall health service utilization and improved
patient outcomes. Further work will be needed to deter-
mine the rate of adoption of the newer guidelines and the
facilitators and barriers to adoption. For example, it is
unclear how well guidelines apply to patients above age
85 or the frail elderly.
This study is a population-based study in the real world.
The study included cardiovascular risk factors, and docu-
mentation of kidney disease unlike many survey
reports[26]. Drug data was recorded by patient self-report
at each visit by Diabetes Centre personnel. The quality of
the DCPNS Registry evolved over time, particularly the
details related to antihypertensive drug therapy. Self-
report has had good concordance with pharmacy claims
data[27,28]. We were unable to determine how patients
used the medications, if antihypertensive medications
were used for hypertension or for another disease, any
contraindications to therapy, the comorbid conditions,
target organ damage, or response to previous antihyper-
tensive therapy. Blood pressure measurements were part
of routine care. Family history of cardiovascular disease,
smoking, and lifestyle factors and the level of blood pres-
sure at which treatment was started were not determined.
Conclusion
Many patients with diabetes mellitus and hypertension
were not treated according to guidelines, with 47% of the
patients meeting the 2003 guidelines definitions of hyper-
tension not being treated with antihypertensive medica-
The effect of clinical practice guidlines changes on the percentage of Nova Scotia patients with diabetes classified as  hypertensive Figure 1
The effect of clinical practice guidlines changes on the percentage of Nova Scotia patients with diabetes classi-
fied as hypertensive.
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tions. By reducing the cutpoints for defining
hypertension, the proportion of people affected increased
substantially. Specific risk factors determined may aid in
identifying patients at high-risk for inadequate treatment.
Patient and provider education, public health approaches,
and health system changes are needed to address these
issues. Further work is needed to determine the reasons
for lack of control, approaches to improve control and
long-term patient outcomes, and the budget impact and
cost effectiveness of using the 2003 guidelines.
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Table 1: Predictors of Treatment among Patients with Hypertension, 2003 Guidelines
Variable Crude Odds Ratio (95% CI) Adjusted Odds Ratio (95% CI)†
Age
≤50 1.00
51–60 1.17 (0.70–1.96)
61–70 1.47 (0.91–2.37)
≥71 1.42 (0.88–2.28)
Gender
Male 1.00
Female 1.26 (0.97–1.63)
Diabetes
Type I 1.55 (0.75–3.18)
Type II 1.00
Treatment *
Diet 1.00 1.00
Oral meds 1.89 (1.31–2.74) 1.89 (1.31–2.74)
Insulin 1.04 (0.77–1.41) 1.04 (0.77–1.41)
Insulin + Oral 2.48 (1.13–5.43) 2.48 (1.13–5.43)
Kidney Disease **
None 1.00
Mild 1.32 (0.90–1.94)
Moderate 0.97 (0.65–1.45)
Severe 1.23 (0.34–4.50)
Failure not valid
Years Since Diagnosis
≤5 1.00
6–10 0.86 (0.62–1.19)
≥11 1.32 (0.98–1.78)
Years Since Referral
≤3 1.00
4–7 0.84 (0.61–1.17)
≥8 0.94 (0.67–1.31)
Weight (KG)
≤55 1.00
56–67 0.78 (0.35–1.71)
68–90 0.87 (0.42–1.80)
≥91 0.99 (0.47–2.06)
* Oral meds mean taking only oral antihyperglycemic medication; Insulin + Oral means patients who are taking insulin plus oral antihyperglycemic 
medication.
** Presence and stage of kidney disease as measured using the Cockroft-Gault formula.
† Treatment was the only significant predictor, and therefore is not adjusted.Cardiovascular Diabetology 2005, 4:11 http://www.cardiab.com/content/4/1/11
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